Loading...
Please wait, while we are loading the content...
Similar Documents
Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes.
| Content Provider | Europe PMC |
|---|---|
| Author | Marrelli, Daniele Ansaloni, Luca Federici, Orietta Asero, Salvatore Carbone, Ludovico Marano, Luigi Baiocchi, Gianluca Vaira, Marco Coccolini, Federico Di Giorgio, Andrea Framarini, Massimo Gelmini, Roberta Palopoli, Carmen Accarpio, Fabio Fagotti, Anna |
| Editor | Houvenaeghel, Gilles |
| Copyright Year | 2022 |
| Abstract | Simple SummaryOvarian cancer is still the most lethal gynecologic malignancy with a median 5-year survival of less than 50%. Most cases are diagnosed at the advanced stages and only limited improvements in overall survival are achieved by standard treatments. Despite the paucity of randomized clinical trials, combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) show encouraging survival outcomes in primary ovarian cancer with peritoneal metastases. It gives rise to the definite need to redefine not only the best treatment option, but also the optimal treatment sequence based on the primary tumor and the extent of disease.AbstractOvarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively. |
| Journal | Cancers |
| Volume Number | 14 |
| PubMed Central reference number | PMC9740463 |
| Issue Number | 23 |
| PubMed reference number | 36497490 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers14236010 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-12-06 |
| Access Restriction | Open |
| Rights License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). © 2022 by the authors. |
| Subject Keyword | advanced ovarian cancer peritoneal metastases neoadjuvant chemotherapy hyperthermic intraperitoneal chemotherapy cytoreductive surgery |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |
